For further details see:
BeiGene, Strand Therapeutics ink immuno-oncology pactFor further details see:
BeiGene, Strand Therapeutics ink immuno-oncology pactMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
BeiGene Ltd. Company Name:
BGNE Stock Symbol:
Market:
U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday. Shares of Lululemon Athletica Inc. (NASDAQ: L...
On Thursday, the FDA approved BeiGene Ltd’s (NASDAQ:BGNE) approved Tevimbra (tislelizumab-jsgr) as monotherapy for adult patients w...
Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy Approval represents the first indication in the U.S. for TEVIMBRA BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE:...